<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137396</url>
  </required_header>
  <id_info>
    <org_study_id>0911005989</org_study_id>
    <secondary_id>DA011744-08</secondary_id>
    <nct_id>NCT01137396</nct_id>
  </id_info>
  <brief_title>Modafinil, Sleep Architecture and Cocaine Relapse</brief_title>
  <official_title>Modafinil, Sleep Architecture and Cocaine Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The medication modafinil has been shown to reduce cocaine use in some cocaine users. The
      investigators have shown that modafinil taken in the morning improves sleep in chronic
      cocaine users. The investigators hypothesize that the beneficial effects of modafinil in
      reducing cocaine use may be related to specific effects modafinil has on sleep. This study
      will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using
      cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%Cocaine Free Urines</measure>
    <time_frame>3x/week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in N3 (Slow-wave) Sleep Time</measure>
    <time_frame>change from week 1 to week 2 of inpatient treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>Modafinil 400mg PO QDaily following up-titration for ~8weeks</description>
    <arm_group_label>Modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>Once weekly cognitive behavioral therapy for cocaine dependence</description>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25-50 years of age;

          -  voluntary, written, informed consent;

          -  seeking but not currently enrolled in treatment for cocaine use;

          -  self-reported, current use of cocaine by smoked or intravenous route at least one time
             each week in the past month, with ≥1g used within a single 24-hour period and ≥3g used
             in the month;

          -  positive urine test for cocaine (benzoylecognine) at the time of screening and study
             start

          -  dependence on cocaine in the past year as measured by a score ≥ 3 on the Severity of
             Dependence Scale(Kaye and Darke, 2002);

          -  chronic use in the past year as determined by self-reported use in at least 9 of the
             past 12 months;

          -  lifetime diagnosis of cocaine dependence with a duration of at least 2 years as
             determined by the Structured Clinical Interview for DSM-IV (SCID).

        Exclusion Criteria:

          -  evidence of any neurological condition or a chronic medical condition including
             diabetes, cardiovascular disease or history of cardiac problems, HIV-seropositivity,
             liver disease, hypertension, asthma requiring daily medication, dementia, movement
             disorder, history of head trauma with loss of consciousness, sleep apnea, narcolepsy,
             restless leg syndrome, periodic limb movement disorder, REM sleep disorder,
             pharmacological treatment for insomnia of any type within the past 6 months, glaucoma,
             severe respiratory insufficiency, seizure disorder, or if in the past three months
             they have taken any medications that affect sleep, or are currently taking any
             regularly dosed prescription medication or any prn medication that is used on average
             more than 1x/week

          -  evidence of chronic sleep disorder including sleep apnea, narcolepsy, periodic limb
             movement disorder, restless leg syndrome as determined by medical history, Sleep
             Disorders Questionnaire(Douglass, 1994), or by polysomnography (following enrollment)

          -  current dependence on any drugs other than cocaine or nicotine or lifetime dependence
             on alcohol, benzodiazepines, or opiates, or any non-substance related Axis I disorder
             as determined by SCID

          -  current use of alcohol in excess of 3x/week AND 21 standard drinks/week in the past
             month or non-zero breathalyzer at screening or study start

          -  current use of cannabis in the past month

          -  positive urine toxicology test for opiates, methadone, amphetamines, barbiturates,
             benzodiazepines, PCP, methaquolone, and propoxyphene at the time of screening or
             positive test for any of those listed plus cannabis at the time of study start

          -  pregnancy as determined by serum β-HCG at screening or lactating per report

          -  females: unwillingness to use barrier contraceptives during sexual intercourse for the
             duration of the study

          -  known hypersensitivity to modafinil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Morgan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <results_first_submitted>March 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2016</results_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Modafinil</title>
          <description>Modafinil: Modafinil 400mg PO QDaily following up-titration for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo medication Qdaily for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modafinil</title>
          <description>Modafinil: Modafinil 400mg PO QDaily following up-titration for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo medication Qdaily for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="7"/>
                    <measurement group_id="B2" value="44" spread="7"/>
                    <measurement group_id="B3" value="43" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>%Cocaine Free Urines</title>
        <time_frame>3x/week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil: Modafinil 400mg PO QDaily following up-titration for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo medication Qdaily for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
          </group>
        </group_list>
        <measure>
          <title>%Cocaine Free Urines</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="9"/>
                    <measurement group_id="O2" value="26" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in N3 (Slow-wave) Sleep Time</title>
        <time_frame>change from week 1 to week 2 of inpatient treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil: Modafinil 400mg PO QDaily following up-titration for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo medication Qdaily for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Change in N3 (Slow-wave) Sleep Time</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="4"/>
                    <measurement group_id="O2" value="-2.5" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Modafinil</title>
          <description>Modafinil: Modafinil 400mg PO QDaily following up-titration for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo medication Qdaily for ~8weeks
Cognitive Behavioral Therapy: Once weekly cognitive behavioral therapy for cocaine dependence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Morgan</name_or_title>
      <organization>Yale University</organization>
      <phone>203-974-7560</phone>
      <email>peter.morgan@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

